The present embodiments relate to the field of treating cardiac malfunction, and more particularly, to methods and systems for stimulating the heart to treat cardiac malfunction, such as congestive heart failure.
Methods and systems for treating cardiac malfunction are disclosed.
In one aspect, a method for treating cardiac malfunction may include delivering a stimulation pattern of stimulation pulses to at least one cardiac chamber of a heart. At least one of the stimulation pulses may have a first stimulation setting configured to reduce at least one of end systolic volume (ESV) and end diastolic volume (EDV) in the heart, and at least one of the stimulation pulses may have a second stimulation setting different from the first stimulation setting. The stimulation pattern may be configured to reduce the at least one of end systolic volume (ESV) and end diastolic volume (EDV) by at least 5% and to maintain the at least one of end systolic volume (ESV) and end diastolic volume (EDV) on average at such reduced volume for a time period of at least one hour.
In another aspect, a system for treating cardiac malfunction may include a stimulation circuit and at least one controller. The stimulation circuit may be configured to deliver a stimulation pulse to at least one cardiac chamber of a heart of a patient. The at least one controller may be configured to execute delivery of a stimulation pattern of stimulation pulses to the at least one cardiac chamber. At least one of the stimulation pulses may have a first stimulation setting configured to reduce at least one of end systolic volume (ESV) and end diastolic volume (EDV) in the heart, and at least one of the stimulation pulses may have a second stimulation setting different from the first stimulation setting. The stimulation pattern may be configured to reduce the at least one of end systolic volume (ESV) and end diastolic volume (EDV) by at least 5% and maintain the at least one of the end systolic volume (ESV) and end diastolic volume (EDV) on average at such reduced volume for a time period of at least one hour.
Other systems, methods, features, and advantages of the present embodiments will be, or will become, apparent to one of ordinary skill in the art upon examination of the following figures and detailed description. It is intended that all such additional systems, methods, features and advantages be included within this description and this summary, be within the scope of the embodiments, and be protected by the following claims.
The embodiments can be better understood with reference to the following drawings and description. The components in the figures are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the embodiments. Moreover, in the figures, like reference numerals designate corresponding parts throughout the different views.
A healthy cardiac contraction cycle includes two phases: a systole and a diastole. The systole is a period of cardiac contraction, commencing with ventricular contraction. The systole causes blood to be ejected from the heart and into the vascular system. At the end of this contraction, cardiac muscles relax. This period of relaxation is the diastole. During diastole, the heart passively fills with blood from the vascular system and at the end of diastole the atria contract and provide additional filling to the ventricle. Accordingly, at the end of the diastole and just before the heart begins to contract, cardiac blood volume peaks. This peak volume is the end diastolic volume (EDV). At the end of the systole, when contraction ends and cardiac filling is about to commence, cardiac blood volume reaches a minimal value. This minimal volume is the end systolic volume (ESV). The amount of blood ejected in a heartbeat is known as the stroke volume (SV) and equals the difference between end diastolic volume (EDV) and end systolic volume (ESV). The ejection fraction (EF) is the fraction of blood that is ejected by the heart (i.e., SV divided by EDV).
Cardiac remodeling is a phenomenon that results from cardiac load or injury, and is an accepted determinant of the clinical course of heart failure (HF). It manifests clinically as changes in size, shape, and function of the heart.
As a result of damage to the heart, abnormal strain patterns are manifested in the heart, and the cells that experience a high strain undergo hypertrophy and some loss of function. This affects cardiac function and blood pressure parameters, and as a consequence, neuronal and/or hormonal pathways are activated in an attempt to compensate for cardiac damage. For example, poor contraction results in high end systolic volume (ESV) and thus a reduction in stroke volume (SV). This may lead to increase in end diastolic volume (EDV) as well. As cardiac volumes increase, so does the wall tension in the heart, as known from Laplace's Law. According to the law, a dilated ventricle requires more tension in the wall to generate the same pressure as would a smaller ventricle. This increase in tension increases sympathetic stimulation and vasopressin (antidiuretic hormone or ADH) secretion. Vasopressin is known to constrict blood vessels and increase heart rate, which causes an increase in blood pressure and an increase in oxygen consumption by the heart muscle cells. However, this also causes an additional increase in cardiac strain, since the heart beats faster and in every systole needs to eject blood against a system showing an increased resistance. This increased strain may cause additional hypertrophy and further loss of function. Thus, a vicious cycle comes into play where the cardiovascular system's attempts at reducing the effect of the damaged tissue cause additional reduction in cardiac performance.
Many attempts have been made to develop devices and methods to treat heart failure, including, for example, devices intended to mechanically control cardiac volumes:
Interfering with cardiac filling may reduce blood pressure in hypertensive patients. One option for interfering with cardiac filling to reduce blood pressure may be to reduce or even eliminate atrial kick. Atrial kick may provide a relatively small boost to ventricle filling (10-30%) that is caused by atrial contraction before an atrioventricular (AV) valve between the atrium and the ventricle is closed. Once the ventricle begins to contract, pressure builds up in the ventricle and causes the AV valve to passively close. The inventors also found that when effecting treatment that reduces or even eliminates atrial kick, the cardiovascular system acts to adapt to the change and return performance values to those that occurred before treatment commenced. International Publications Nos. WO2015/094401 and WO2014/100429, both to Mika et al., and both herein incorporated by reference in their entirety, describe, inter alia, methods and systems providing pacing patterns of stimulation pulses that comprise pulses configured to reduce or prevent atrial kick and also reduce or even eliminate the cardiovascular system's adaptation to the reduction in blood pressure. The reduction in adaptation may be achieved by reducing neurohormonal response to changes in generated pressure and stretch using specific patterns.
Heart failure patients, on the other hand, typically (although not exclusively) have blood pressure values that are not significantly elevated. Accordingly, in some cases, it may be preferred to reduce cardiac volumes (e.g., at least one of end diastolic volume and end systolic volume) and/or reduce cardiac strain without significantly affecting blood pressure.
The inventors have developed methods and systems of applying cardiac stimulations that yield surprising results in meeting the needs of heart failure patients. Embodiments provide methods and system that may reduce the strain sensed by cardiac muscles by applying cardiac stimulations that reduce at least one of end systolic volume (ESV) and end diastolic volume (EDV) without significantly affecting the ejection fraction (EF) of the heart, and optionally also without significantly affecting blood pressure. A reduction of such strain may be useful in reversing cardiac remodeling or at least in slowing down or even stopping the remodeling process. In some embodiments, a stimulation pattern may be configured to reduce a neurohormonal response to changes in strain without significantly affecting blood pressure.
Optionally, when a patient is provided with a cardiac stimulation device, a stimulation pattern is selected based on sensing of one or more of: at least one blood-pressure-related parameter (e.g., an indication of pretreatment and/or treatment blood pressure) and at least one cardiac-strain and/or volume-related parameter (e.g., a pressure measurement within a chamber and/or echocardiogram-derived information). These parameters can be used to adjust one or more of the properties of one or more (or two or more) pulses in a pulse pattern and/or the proportion between pulses having different settings and/or the order of the pulses in the pattern. Optionally, reducing at least one of end diastolic volume (EDV) and end systolic volume (ESV) suppresses sympathetic stimulation, for example, by at least one of reducing wall strain and hence reducing or eliminating the activation of sympathetic pathways involved with adaptation of the cardiovascular system to changes.
Optionally, a device is configured to receive feedback information regarding one or more of the at least one blood-pressure-related parameter and at least one cardiac strain/volume related parameter. This may be performed periodically (e.g., in a periodic measurement such as a periodic checkup) and/or ongoing (e.g., with an associated or integral sensor). The information may be received, for example, via communication with a user through an input interface and/or by communication with implanted and/or external devices. Further details of suitable devices are described below in reference to
A stimulation setting means one or more parameters of one or more stimulation pulses delivered in a single cardiac cycle. For example, these parameters may include one or more of: a time interval between electrical pulses that are included in a single stimulation pulse (e.g., AV delay), a period of delivery with respect to the natural rhythm of the heart, the length of a stimulation pulse or a portion thereof, and the site of delivery between two or more chambers. In some embodiments, a pulse setting includes applying an excitatory pulse to a ventricle, timed in synchronization to the natural activity of an atrium of the heart. In some embodiments, a pulse setting includes applying an excitatory pulse to an atrium timed in synchronization to the natural activity of a ventricle of the heart. In some embodiments, a pulse setting includes applying an excitatory pulse to each of a ventricle and an atrium.
A stimulation pattern may include a series of pulses having identical stimulation settings or a stimulation pattern may include multiple pulses each having different stimulation settings. For example, a stimulation pattern may have one or more pulses having a first setting and one or more pulses having a second setting that is different from the first setting. When stating that a stimulation pattern has a setting, it is understood that this means a stimulation pattern may include at least one stimulation pulse having that setting. It is also understood that, in some embodiments a stimulation pattern may include one or more cardiac cycles where no stimulation pulse is delivered, in which case the pulse(s) may be viewed as being delivered at zero power. A stimulation pattern may include a plurality of identical pulses or a sequence of pulses including two or more different settings. Two stimulation sequences in a pattern may differ in the order of pulses provided within a setting. Two or more stimulation sequences may optionally differ in their lengths (in time and/or number of heartbeats). In some embodiments, a stimulation pattern may include pulses having blood pressure reduction (BPR) settings. In some embodiments, a stimulation pattern may include pulses that do not have BPR settings.
Experimental Results
In an experiment according to a first embodiment, a plurality of patients' hearts were paced at the ventricle and atrium using a pacing pattern that included 9 to 10 pulses having a first stimulation setting (according to which the ventricle was stimulated 40-90 milliseconds after atrial activation) and 1 to 2 pulses having a second stimulation setting (according to which the ventricle was stimulated 100-180 milliseconds after atrial activation). Pulses having the first stimulation setting reduced atrial kick, while pulses having the second stimulation setting did not do so. The pacing pattern was applied continuously for a period of up to about six months. Changes in end systolic volume (ESV), end diastolic volume (EDV), and ejection fraction (EF) were derived from echocardiogram data.
Before treatment, end systolic volume (ESV) and end diastolic volume (EDV) were measured and ejection fraction (EF) was calculated to provide baseline (BL) values for each patient. Thereafter, the same values were obtained approximately one, two, three, and six months after treatment commenced, and the change from baseline (BL) for each patient was calculated. Each of
As shown in
Before treatment, end systolic volume (ESV) and end diastolic volume (EDV) were measured and ejection fraction (EF) was calculated to provide baseline (BL) values for each patient. Thereafter, the same values were obtained eight times after treatment commenced, and the change from baseline (BL) for each patient was calculated. The eight times were at approximately the following months after treatment commenced: one, two, three, six, twelve, eighteen, and twenty-four. Each of
As shown in
In light of the experimental results, embodiments provide methods and systems for treating cardiac malfunction. In a first aspect, a method for treating cardiac malfunction may include delivering a stimulation pattern of stimulation pulses to at least one cardiac chamber of a heart. At least one of the stimulation pulses may have a first stimulation setting configured to reduce at least one of end systolic volume (ESV) and end diastolic volume (EDV) in the heart and at least one of the stimulation pulses may have a second stimulation setting different from the first stimulation setting. The stimulation pattern may be configured to reduce the at least one of end systolic volume (ESV) and end diastolic volume (EDV) by at least 5% and maintain the at least one of end systolic volume (ESV) and end diastolic volume (EDV) on average at such reduced volume for a time period of at least one hour.
In a second aspect, the time period may be at least three months.
In a third aspect, the method of the first or second aspect may include a stimulation pattern configured to reduce cardiac strain by at least 2% and maintain the cardiac strain on average at such reduced strain for the time period.
In a fourth aspect, the method of any of the preceding aspects may include a stimulation pattern configured to maintain blood pressure within an average pressure of ±10% as compared to a pretreatment blood pressure value for the time period.
In a fifth aspect, the method of any of the preceding aspects may include a stimulation pattern configured to prevent cardiac remodeling in the patient.
In a sixth aspect, the method of any of the preceding aspects may provide that the first stimulation setting is configured to reduce or prevent atrial kick in at least one ventricle and at least one of the stimulation pulses has a second stimulation setting different from the first stimulation setting.
In a seventh aspect, the method of any of the preceding aspects may provide that the first stimulation setting is configured to reduce the at least one of end systolic volume (ESV) and end diastolic volume (EDV) by at least 5% and the second stimulation setting is configured to reduce a baroreflex response or adaptation to the reduction in the at least one of end systolic volume (ESV) and end diastolic volume (EDV). In some embodiments, the stimulation pattern is configured not to activate a baroreceptor of the patient.
In an eighth aspect, the method of any of the preceding aspects may provide that the stimulation pattern is configured to reduce a baroreflex response or adaptation to the reduction in the at least one of end systolic volume (ESV) and end diastolic volume (EDV).
In a ninth aspect, the method of any of the preceding aspects may provide that the first stimulation setting is configured to reduce the at least one of end systolic volume (ESV) and end diastolic volume (EDV) by at least 5% and the second stimulation setting is configured to reduce a neuronal response or adaptation to the reduction in the at least one of end systolic volume (ESV) and end diastolic volume (EDV).
In a tenth aspect, the method of any of the preceding aspects may provide that the stimulation pattern is configured to reduce a neuronal response or adaptation to the reduction in the at least one of end systolic volume (ESV) and end diastolic volume (EDV).
In an eleventh aspect, the method of any of the preceding aspects may provide that the first stimulation setting is configured to reduce the at least one of end systolic volume (ESV) and end diastolic volume (EDV) by at least 5% and the second stimulation setting is configured to increase hormonal secretion.
In a twelfth aspect, the method of any of the preceding aspects may provide that the stimulation pattern is configured to increase hormonal secretion.
In a thirteenth aspect, the method of any of the preceding aspects may provide that the first stimulation setting comprises stimulating a ventricle of the heart 40-90 milliseconds after atrial activation.
In a fourteenth aspect, the method of the thirteenth aspect may provide that the second stimulation setting comprises stimulating an atrium of the heart to thereby produce atrial stimulation.
In a fifteenth aspect, the method of any of the preceding aspects may provide that the second stimulation setting comprises stimulating a ventricle of the heart 100-180 milliseconds after atrial activation.
In a sixteenth aspect, the method of any of the first aspect through fourteenth aspect may provide that the second stimulation setting comprises allowing a natural AV delay to occur.
In a seventeenth aspect, the method of any of the preceding aspects may provide that the stimulation pattern includes at least 4 consecutive heartbeats having the first stimulation setting for every 1 consecutive heartbeat having the second stimulation setting.
In an eighteenth aspect, the method of the seventeenth aspect may provide that the stimulation pattern includes at least 8 consecutive heartbeats having the first stimulation setting for every 1 consecutive heartbeat having the second stimulation setting.
In a nineteenth aspect, the method of any of the preceding aspects may provide that the stimulation pattern comprises at least one stimulation pulse having a third stimulation setting different from the first and second stimulation settings.
In a twentieth aspect, the method of any of the preceding aspects may provide that the cardiac malfunction is associated with an increase in at least one of end systolic volume (ESV) and end diastolic volume (EDV).
In a twenty-first aspect, the method of any of the preceding aspects may provide that the cardiac malfunction is congestive heart failure.
In a twenty-second aspect, the method of any of the preceding aspects may further include applying the stimulation pattern at a stimulation pattern configuration for a first period, sensing at least one parameter indicative of at least one of end systolic volume (ESV), end diastolic volume (EDV), cardiac strain, and blood pressure for the first period, and adjusting the stimulation pattern configuration according to the sensing.
In a twenty-third aspect, the method of the twenty-second aspect may provide that adjusting the stimulation pattern includes adjusting at least one of the first stimulation setting and the second stimulation setting.
In a twenty-fourth aspect, the method of either the twenty-second or twenty-third aspect may provide that adjusting the stimulation pattern configuration includes adjusting at least one of the number and proportion of at least one of stimulation pulses having the first stimulation setting and stimulation pulses having the second stimulation setting within the stimulation pattern.
Another aspect provides a system for treating cardiac malfunction. The system may include a stimulation circuit configured to deliver a stimulation pulse to at least one cardiac chamber of a heart of a patient, and at least one controller configured to execute delivery of a stimulation pattern of stimulation pulses to the at least one cardiac chamber. At least one of the stimulation pulses may have a first stimulation setting configured to reduce at least one of end systolic volume (ESV) and end diastolic volume (EDV) in the heart and at least one of the stimulation pulses may have a second stimulation setting different from the first stimulation setting. The stimulation pattern may be configured to reduce the at least one of end systolic volume (ESV) and end diastolic volume (EDV) by at least 5% and maintain the at least one of end systolic volume (ESV) and end diastolic volume (EDV) on average at such reduced volume for a time period of at least one hour.
In a further aspect of the system, the at least one controller may be configured to receive input data relating to at least one sensed parameter indicative of at least one of end systolic volume (ESV), end diastolic volume (EDV), cardiac strain, and blood pressure for the time period and to adjust the stimulation pattern configuration according to the at least one sensed parameter.
In a further aspect of the system, the system may further comprise at least one sensor configured to sense the at least one sensed parameter and to communicate the input data to the at least one controller.
In a further aspect of the system, the at least one controller, the stimulation circuit, and the at least one sensor may be combined in a single device.
System 800 may include a biocompatible body 51, one or more controllers 52, a power source 53, and a telemetry unit 56. Body 51 may comprise a housing for encasing a plurality of components of the system. Controller(s) 52 may be configured to control the operation of the system, and may implement any of the embodiments and methods disclosed herein. For example, controller(s) 52 may control the delivery of stimulation pulses. In some embodiments, power source 53 may include a battery. For example, power source 53 may include a rechargeable battery. In some embodiments, power source 53 may include a battery that is rechargeable by induction. In some embodiments, telemetry unit 56 may be configured to communicate with one or more other units and/or components. For example, telemetry unit 56 may be configured to communicate with an external programmer and/or a receiving unit for receiving data recorded on system 800 during operation.
In some embodiments, system 800 may include one or more electrodes and/or sensors. The electrodes and/or sensors may be integrated in system 800, attached thereto, and/or connectable therewith. In some embodiments, the electrodes may include ventricular electrode(s) 561 configured to pace at least one ventricle. Additionally or alternatively, the system may be connected, optionally via wires or wirelessly, to at least one implanted artificial valve 562. Additionally, system 800 may comprise one or more atrial electrode(s) 57 for pacing one or more atria, and/or one or more atrial sensors 58 for sensing the onset of atrial excitation, and/or one or more sensors 59 for providing other feedback parameters (e.g., a blood-pressure-related parameter and a cardiac strain/volume related parameter).
In some embodiments, sensor(s) 59 may comprise one or more pressure sensors, electrical sensors (e.g., ECG monitoring), flow sensors, heart rate sensors, activity sensors, and/or volume sensors. Sensor(s) 59 may include mechanical sensors and/or electronic sensors (e.g., ultrasound sensors, electrodes, and/or RF transceivers). In some embodiments, sensor(s) 59 may communicate with system 800 via telemetry.
In some embodiments, ventricular electrode(s) 561 and/or atrial electrode(s) 57 may be standard pacing electrodes. Ventricular electrode(s) 561 may be positioned relative to the heart at positions as known in the art for ventricular pacing. For example, ventricular electrode(s) may be placed in and/or near one or more of the ventricles. In some embodiments, atrial electrode(s) 57 may be placed in and/or near one or more of the atria. In some embodiments, atrial electrode(s) 57 may be attached to the one or more atria at one or more positions selected to provide early detection of atrial excitation or depolarization. For example, in some embodiments, atrial electrode(s) 57 may be attached to the right atrium near the site of the sinoatrial (SA) node.
One position of ventricular electrode(s) 561 may be such that pacing may reduce or minimize the prolongation of QRS when the heart is paced, to reduce or even minimize dyssynchrony. In some embodiments, this position is on the ventricular septum near the Bundle of His. Ventricular electrode(s) 561 may additionally or alternatively be placed on the epicardium of the heart or in coronary veins. More than one electrode can be placed on the ventricles to provide biventricular pacing, optionally to reduce dyssynchrony.
System 800 may include a pulse generator, or stimulation circuit, configured to deliver a stimulation pulse to at least one cardiac chamber. The pulse generator, or stimulation circuit, may include some or all standard capabilities of a conventional pacemaker. Controller 52 may be configured to control the pulse generator, or stimulation circuit. Atrial sensor(s) 58 (and optionally other electrode sensors configured to sense other heart chambers) may be connected to system 800 via specific circuits that amplify the electrical activity of the heart and allow sampling and detection of the activation of the specific chamber. Other circuits may be configured to deliver stimulation to a specific electrode to pace the heart, creating propagating electrical activation.
In some embodiments, one or more additional sensors 59 may be placed in and/or on one or more of the atria and/or in and/or on one or more of the ventricles and/or in and/or on one or more other locations that might optionally be adjacent the heart. For example, one or more sensors may be placed on and/or in vena cava and/or on one or more arteries and/or within one or more cardiac chambers. These sensors may measure pressure, or other indicators, such as, for example, impedance and/or flow.
In some embodiments, controller 52 may comprise or be a microprocessor powered by power source 53. In some embodiments, system 800 may comprise a clock 54, for example, generated by a crystal. System 800 may comprise an internal memory 55 and/or be connected to external memory. For example, device may connect to an external memory via telemetry unit 56. In some embodiments, telemetry unit 56 may be configured to allow communication with external devices such as a programmer and/or one or more of sensors 59. Any and all feedback information and/or a log of device operation may be stored in internal memory 55 and/or relayed by telemetry unit 56 to an external memory unit.
In some embodiments, controller 52 may operate in accordance with at least one embodiment of a method described herein.
In some embodiments, system 800 may comprise one or more sensors for sensing one or more feedback parameters to control the application of the AV delay and/or its magnitude.
According to further embodiments, additional systems and devices suitable for implementing the methods presented herein are described in U.S. Pat. No. 9,370,662 to Mika et al., issued Jun. 21, 2016, for example, in reference to FIGS. 9 and 14 of that patent. The entirety of U.S. Pat. No. 9,370,662 is herein incorporated by reference.
The foregoing disclosure has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the embodiments to the precise forms disclosed. Many variations and modifications of the embodiments described herein will be apparent to one of ordinary skill in the art in light of the above disclosure.
While various embodiments have been described, the description is intended to be exemplary, rather than limiting and it will be apparent to those of ordinary skill in the art that many more embodiments and implementations are possible that are within the scope of the embodiments. Any feature of any embodiment may be used in combination with or substituted for any other feature or element in any other embodiment unless specifically restricted. Accordingly, the embodiments are not to be restricted except in light of the attached claims and their equivalents. Also, various modifications and changes may be made within the scope of the attached claims.
Further, in describing representative embodiments, the specification may have presented a method and/or process as a particular sequence of steps. However, to the extent that the method or process does not rely on the particular order of steps set forth herein, the method or process should not be limited to the particular sequence of steps described. As one of ordinary skill in the art would appreciate, other sequences of steps may be possible. Therefore, the particular order of the steps set forth in the specification should not be construed as limitations on the claims. In addition, the claims directed to the method and/or process should not be limited to the performance of their steps in the order written, and one skilled in the art can readily appreciate that the sequences may be varied and still remain within the spirit and scope of the present embodiments.
This application is a continuation of U.S. application Ser. No. 15/259,282, filed Sep. 8, 2016, now U.S. Pat. No. 10,342,982, issued Jul. 9, 2019, which claims the benefit of U.S. Provisional Application No. 62/217,299, filed Sep. 11, 2015, both of which are herein incorporated by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
3683934 | Bukowiecki et al. | Aug 1972 | A |
3814106 | Berkovits | Jun 1974 | A |
3939844 | Pequignot | Feb 1976 | A |
4407287 | Herpers | Oct 1983 | A |
4712555 | Thornander et al. | Dec 1987 | A |
4719921 | Chirife | Jan 1988 | A |
4899752 | Cohen | Feb 1990 | A |
5063239 | Schwenner et al. | Nov 1991 | A |
5154171 | Chirife | Oct 1992 | A |
5163429 | Cohen | Nov 1992 | A |
5199428 | Obel et al. | Apr 1993 | A |
5213098 | Bennett et al. | May 1993 | A |
5318595 | Ferek-Petric et al. | Jun 1994 | A |
5584868 | Salo et al. | Dec 1996 | A |
5601613 | Florio et al. | Feb 1997 | A |
5601615 | Markowitz et al. | Feb 1997 | A |
5612380 | Lerner et al. | Mar 1997 | A |
5713928 | Bonnet et al. | Feb 1998 | A |
5800334 | Wilk | Sep 1998 | A |
5891176 | Bornzin | Apr 1999 | A |
5928271 | Hess et al. | Jul 1999 | A |
5971911 | Wilk | Oct 1999 | A |
6045531 | Davis | Apr 2000 | A |
6241678 | Afremov et al. | Jun 2001 | B1 |
6271015 | Gilula et al. | Aug 2001 | B1 |
6314322 | Rosenberg | Nov 2001 | B1 |
6377852 | Bornzin et al. | Apr 2002 | B1 |
6450942 | Lapanashvili et al. | Sep 2002 | B1 |
6507756 | Heynen et al. | Jan 2003 | B1 |
6580946 | Struble | Jun 2003 | B2 |
6628988 | Kramer et al. | Sep 2003 | B2 |
6666826 | Salo et al. | Dec 2003 | B2 |
6668195 | Warman et al. | Dec 2003 | B2 |
6699682 | Gilula et al. | Mar 2004 | B2 |
6701187 | Bornzin et al. | Mar 2004 | B1 |
6795732 | Stadler et al. | Sep 2004 | B2 |
6832113 | Belalcazar | Dec 2004 | B2 |
7001611 | Kiso et al. | Feb 2006 | B2 |
7092759 | Nehls et al. | Aug 2006 | B2 |
7096064 | Deno et al. | Aug 2006 | B2 |
7098233 | Di Cesare et al. | Aug 2006 | B2 |
7103410 | Kramer et al. | Sep 2006 | B2 |
7155284 | Whitehurst et al. | Dec 2006 | B1 |
7184832 | Deno et al. | Feb 2007 | B2 |
7233824 | Kleckner et al. | Jun 2007 | B2 |
7286873 | Havel et al. | Oct 2007 | B2 |
7289849 | Baynham et al. | Oct 2007 | B2 |
7346394 | Liu et al. | Mar 2008 | B2 |
7348173 | Gilula et al. | Mar 2008 | B2 |
7363077 | Min et al. | Apr 2008 | B1 |
7548782 | Kramer et al. | Jun 2009 | B2 |
7580747 | Farazi et al. | Aug 2009 | B1 |
7618364 | Walsh et al. | Nov 2009 | B2 |
7651461 | Alferness et al. | Jan 2010 | B2 |
7674222 | Nikolic et al. | Mar 2010 | B2 |
7676264 | Pillai et al. | Mar 2010 | B1 |
7711420 | Baynham et al. | May 2010 | B2 |
7725173 | Viertio-Oja et al. | May 2010 | B2 |
7725185 | Liu et al. | May 2010 | B2 |
7765008 | Ben-Haim et al. | Jul 2010 | B2 |
7869874 | Levin et al. | Jan 2011 | B2 |
7877144 | Coles, Jr. et al. | Jan 2011 | B2 |
7908008 | Ben-David et al. | Mar 2011 | B2 |
3019416 | Pastore et al. | Sep 2011 | A1 |
8027724 | Wei et al. | Sep 2011 | B2 |
8046070 | Salo et al. | Oct 2011 | B2 |
8086315 | Schwartz et al. | Dec 2011 | B2 |
8165674 | Levin et al. | Apr 2012 | B2 |
8187160 | Criscione et al. | May 2012 | B2 |
8224444 | Ben-David et al. | Jul 2012 | B2 |
8295928 | Salo et al. | Oct 2012 | B2 |
8340763 | Levin et al. | Dec 2012 | B2 |
8428729 | Schwartz et al. | Apr 2013 | B2 |
8504149 | Libbus et al. | Aug 2013 | B2 |
8515536 | Levin et al. | Aug 2013 | B2 |
8521280 | Levin et al. | Aug 2013 | B2 |
8571656 | Stahmann et al. | Oct 2013 | B2 |
8805494 | Libbus et al. | Aug 2014 | B2 |
9008769 | Mika et al. | Apr 2015 | B2 |
9108062 | Stahmann et al. | Aug 2015 | B2 |
9320903 | Schwartz et al. | Apr 2016 | B2 |
9333352 | Mika et al. | May 2016 | B2 |
9370661 | Levin et al. | Jun 2016 | B2 |
9370662 | Mika et al. | Jun 2016 | B2 |
9427586 | Levin et al. | Aug 2016 | B2 |
9526900 | Mika et al. | Dec 2016 | B2 |
9592390 | Stahmann et al. | Mar 2017 | B2 |
9656086 | Mika et al. | May 2017 | B2 |
9687636 | Levin et al. | Jun 2017 | B2 |
9731136 | Levin et al. | Aug 2017 | B2 |
9878162 | Mika et al. | Jan 2018 | B2 |
9937351 | Mika et al. | Apr 2018 | B2 |
10004905 | Stahmann et al. | Jun 2018 | B2 |
10071250 | Mika et al. | Sep 2018 | B2 |
10173067 | Shuros et al. | Jan 2019 | B2 |
10232183 | Schwartz et al. | Mar 2019 | B2 |
10252060 | Levin et al. | Apr 2019 | B2 |
10252061 | Mika et al. | Apr 2019 | B2 |
10342982 | Mika et al. | Jul 2019 | B2 |
10369333 | Levin et al. | Aug 2019 | B2 |
10441794 | Mika et al. | Oct 2019 | B2 |
10485658 | Mika et al. | Nov 2019 | B2 |
10596380 | Levin et al. | Mar 2020 | B2 |
10610689 | Mika et al. | Apr 2020 | B2 |
10835751 | Stahmann et al. | Nov 2020 | B2 |
11083894 | Levin et al. | Aug 2021 | B2 |
11097108 | Mika et al. | Aug 2021 | B2 |
20020161410 | Kramer et al. | Oct 2002 | A1 |
20020173826 | Lincoln et al. | Nov 2002 | A1 |
20030060858 | Kieval et al. | Mar 2003 | A1 |
20030083700 | Hill et al. | May 2003 | A1 |
20030144702 | Yu et al. | Jul 2003 | A1 |
20030144703 | Yu et al. | Jul 2003 | A1 |
20030176896 | Lincoln et al. | Sep 2003 | A1 |
20030199934 | Struble et al. | Oct 2003 | A1 |
20040015081 | Kramer et al. | Jan 2004 | A1 |
20040044361 | Frazier et al. | Mar 2004 | A1 |
20040049235 | Deno et al. | Mar 2004 | A1 |
20040138715 | Van Groeningen et al. | Jul 2004 | A1 |
20040167410 | Hettrick | Aug 2004 | A1 |
20040186523 | Florio | Sep 2004 | A1 |
20040199210 | Shelchuk | Oct 2004 | A1 |
20040215255 | Vries | Oct 2004 | A1 |
20040215266 | Struble et al. | Oct 2004 | A1 |
20040215268 | Corbucci | Oct 2004 | A1 |
20050038478 | Klepfer et al. | Feb 2005 | A1 |
20050070952 | Devellian | Mar 2005 | A1 |
20050075676 | Deno et al. | Apr 2005 | A1 |
20050090872 | Deno et al. | Apr 2005 | A1 |
20050101998 | Kleckner et al. | May 2005 | A1 |
20050102002 | Salo et al. | May 2005 | A1 |
20050119285 | Matos et al. | Jun 2005 | A1 |
20050143785 | Libbus | Jun 2005 | A1 |
20050149128 | Heil, Jr. et al. | Jul 2005 | A1 |
20050149130 | Libbus | Jul 2005 | A1 |
20050149131 | Libbus et al. | Jul 2005 | A1 |
20050165454 | Chinchoy | Jul 2005 | A1 |
20050222640 | Schwartz et al. | Oct 2005 | A1 |
20050234543 | Glaser et al. | Oct 2005 | A1 |
20060173502 | Baynham et al. | Aug 2006 | A1 |
20060173504 | Zhu et al. | Aug 2006 | A1 |
20060247702 | Stegemann et al. | Nov 2006 | A1 |
20060264980 | Khairkhahan et al. | Nov 2006 | A1 |
20070073352 | Euler et al. | Mar 2007 | A1 |
20070083243 | Prakash et al. | Apr 2007 | A1 |
20070239037 | Ghio | Oct 2007 | A1 |
20070299475 | Levin et al. | Dec 2007 | A1 |
20070299477 | Kleckner et al. | Dec 2007 | A1 |
20080027488 | Coles et al. | Jan 2008 | A1 |
20080077187 | Levin et al. | Mar 2008 | A1 |
20080109043 | Salo et al. | May 2008 | A1 |
20080114407 | Pastore et al. | May 2008 | A1 |
20080275531 | Bulkes et al. | Nov 2008 | A1 |
20080281368 | Bulkes et al. | Nov 2008 | A1 |
20090018608 | Schwartz et al. | Jan 2009 | A1 |
20090036940 | Wei et al. | Feb 2009 | A1 |
20090069859 | Whinnett et al. | Mar 2009 | A1 |
20090082823 | Shuros et al. | Mar 2009 | A1 |
20090118783 | Patangay et al. | May 2009 | A1 |
20090207028 | Kubey et al. | Aug 2009 | A1 |
20090240298 | Lian et al. | Sep 2009 | A1 |
20090247893 | Lapinlampi et al. | Oct 2009 | A1 |
20090254141 | Kramer et al. | Oct 2009 | A1 |
20090281440 | Farazi et al. | Nov 2009 | A1 |
20090281591 | Shuros et al. | Nov 2009 | A1 |
20090318995 | Keel et al. | Dec 2009 | A1 |
20100069989 | Shipley et al. | Mar 2010 | A1 |
20100087889 | Maskara et al. | Apr 2010 | A1 |
20100094370 | Levin et al. | Apr 2010 | A1 |
20100121397 | Cholette | May 2010 | A1 |
20100121402 | Arcot-Krishnamurthy et al. | May 2010 | A1 |
20100204741 | Tweden et al. | Aug 2010 | A1 |
20110144712 | Stahmann et al. | Jun 2011 | A1 |
20110160787 | Greenhut et al. | Jun 2011 | A1 |
20110172731 | Levin et al. | Jul 2011 | A1 |
20110224749 | Ben-David et al. | Sep 2011 | A1 |
20120041502 | Schwartz et al. | Feb 2012 | A1 |
20120109237 | Xiao et al. | May 2012 | A1 |
20120158082 | Katra | Jun 2012 | A1 |
20120215272 | Levin et al. | Aug 2012 | A1 |
20120215275 | Wenzel et al. | Aug 2012 | A1 |
20130304149 | Kass et al. | Nov 2013 | A1 |
20130331901 | Levin et al. | Dec 2013 | A1 |
20140128934 | Schwartz et al. | May 2014 | A1 |
20140163600 | Levin et al. | Jun 2014 | A1 |
20140163636 | Levin et al. | Jun 2014 | A1 |
20140180353 | Mika | Jun 2014 | A1 |
20150258342 | Mika et al. | Sep 2015 | A1 |
20160129084 | Caggiano et al. | May 2016 | A1 |
20160220824 | Schwartz et al. | Aug 2016 | A1 |
20160243368 | Mika et al. | Aug 2016 | A1 |
20160263383 | Levin et al. | Sep 2016 | A1 |
20160339244 | Levin et al. | Nov 2016 | A1 |
20170080235 | Mika et al. | Mar 2017 | A1 |
20170239481 | Mika et al. | Aug 2017 | A1 |
20170274190 | Levin et al. | Sep 2017 | A1 |
20170291032 | Levin et al. | Oct 2017 | A1 |
20170304048 | Mika et al. | Oct 2017 | A1 |
20180185652 | Mika et al. | Jul 2018 | A1 |
20180256899 | Mika et al. | Sep 2018 | A1 |
20190001141 | Mika et al. | Jan 2019 | A1 |
20190255334 | Schwartz et al. | Aug 2019 | A1 |
20190269927 | Mika et al. | Sep 2019 | A1 |
20190275336 | Levin et al. | Sep 2019 | A1 |
20200009357 | Levin et al. | Jan 2020 | A1 |
20200094060 | Mika et al. | Mar 2020 | A1 |
20200121451 | Mika et al. | Apr 2020 | A1 |
20200254252 | Levin et al. | Aug 2020 | A1 |
20210346702 | Mika et al. | Nov 2021 | A1 |
20220008725 | Levin et al. | Jan 2022 | A1 |
Number | Date | Country |
---|---|---|
2013361318 | Aug 2018 | AU |
2014367229 | Jul 2019 | AU |
2016319787 | Sep 2021 | AU |
2019204758 | Oct 2021 | AU |
2933278 | Jun 2015 | CA |
1446592 | Oct 2003 | CN |
1662278 | Aug 2005 | CN |
2897151 | May 2007 | CN |
101309722 | Nov 2008 | CN |
101980657 | Feb 2011 | CN |
102159279 | Aug 2011 | CN |
102300603 | Dec 2011 | CN |
102551878 | Jul 2012 | CN |
103338709 | Oct 2013 | CN |
106029165 | Oct 2016 | CN |
104968392 | Nov 2017 | CN |
107715299 | Feb 2018 | CN |
108025173 | May 2018 | CN |
106029165 | Nov 2018 | CN |
109219465 | Jan 2019 | CN |
109364374 | Feb 2019 | CN |
107715299 | Jun 2021 | CN |
108025173 | Mar 2022 | CN |
0532148 | Mar 1993 | EP |
2241348 | Oct 2010 | EP |
2374503 | Oct 2011 | EP |
2934669 | Jun 2017 | EP |
3238777 | Nov 2017 | EP |
3082949 | Nov 2018 | EP |
3461531 | Apr 2019 | EP |
3238777 | Oct 2019 | EP |
3639888 | Apr 2020 | EP |
3461531 | Oct 2020 | EP |
3639888 | May 2021 | EP |
3347090 | Nov 2021 | EP |
3954429 | Feb 2022 | EP |
3954429 | May 2022 | EP |
2902005 | Mar 2022 | ES |
1226016 | Oct 2019 | HK |
1243968 | Dec 2021 | HK |
202148037573 | Aug 2021 | IN |
H07171218 | Jul 1995 | JP |
2620819 | Jun 1997 | JP |
2002505172 | Feb 2002 | JP |
2007-519441 | Jul 2007 | JP |
2007527742 | Oct 2007 | JP |
2007-531609 | Nov 2007 | JP |
2010-508979 | Mar 2010 | JP |
2010-509024 | Mar 2010 | JP |
2010-512958 | Apr 2010 | JP |
2010512855 | Apr 2010 | JP |
2010-536481 | Dec 2010 | JP |
2016501639 | Jan 2016 | JP |
2016-540589 | Dec 2016 | JP |
2018-526135 | Sep 2018 | JP |
2019-042579 | Mar 2019 | JP |
6510421 | May 2019 | JP |
2019-517842 | Jun 2019 | JP |
2019-111408 | Jul 2019 | JP |
6831087 | Feb 2021 | JP |
2021013822 | Feb 2021 | JP |
6839163 | Mar 2021 | JP |
6999545 | Dec 2021 | JP |
7050693 | Mar 2022 | JP |
102221586 | Mar 2021 | KR |
102323562 | Nov 2021 | KR |
10-2367191 | Feb 2022 | KR |
9944680 | Sep 1999 | WO |
9944682 | Sep 1999 | WO |
33000252 | Jan 2003 | WO |
2009035515 | Mar 2005 | WO |
2005063332 | Jul 2005 | WO |
2005097256 | Oct 2005 | WO |
2007021258 | Feb 2007 | WO |
2007044279 | Apr 2007 | WO |
2008057631 | May 2008 | WO |
2008063470 | May 2008 | WO |
2008076853 | Jun 2008 | WO |
2008079370 | Jul 2008 | WO |
2012064743 | May 2012 | WO |
2014100429 | Jun 2014 | WO |
2014100429 | Jun 2014 | WO |
2015094401 | Jun 2015 | WO |
2017044794 | Mar 2017 | WO |
2017184912 | Oct 2017 | WO |
Entry |
---|
Response to First Examination Report filed Sep. 27, 2019 in Australian Patent Application No. 2018217270. |
Notice of Allowance dated Sep. 27, 2019 in Hong Kong Patent Application No. 16114537.3. |
Response to Final Office Action filed Sep. 27, 2019 in U.S. Appl. No. 15/226,056. |
Response to Office Action filed Oct. 9, 2019 in European Patent Application No. 16845150.8. |
Second Office Action dated Oct. 14, 2019 in Australian Patent Application No. 2018217270. |
Response to Final Office Action filed Oct. 30, 2019 in U.S. Appl. No. 15/911,249. |
Notice of Allowance dated Nov. 12, 2019 in U.S. Appl. No. 15/226,056. |
European Office Action dated Nov. 15, 2019 in European Patent Application No. 19196148.1. |
Notice of Allowance dated Nov. 22, 2019 in U.S. Appl. No. 15/911,249. |
Extended European Search Report dated Nov. 28, 2019 in European Patent Application No. 17786669.6. |
Response to European Office Action filed Dec. 4, 2019 in European Patent Application No. 19196148.1. |
First Office Action dated Dec. 5, 2019 in Japanese Patent Application No. 2018-238255, and English translation thereof. |
Amendment filed Dec. 3, 2015 in U.S. Appl. No. 13/960,015. |
Notice of Allowance dated Dec. 18, 2015 in U.S. Appl. No. 13/854,283. |
Notice of Allowance dated Jan. 8, 2016 in U.S. Appl. No. 14/642,952. |
Amendment filed Jan. 13, 2016 in U.S. Appl. No. 14/427,478. |
Final Office Action dated Jan. 20, 2016 in U.S. Appl. No. 13/960,015. |
Notice of Allowance dated Feb. 12, 2016 in U.S. Appl. No. 13/688,978. |
Notice of Allowance dated Feb. 12, 2016 in U.S. Appl. No. 14/427,478. |
Office Action dated May 27, 2016 in European Patent Application No. 13826807.3. |
Amendment filed Apr. 7, 2016 in U.S. Appl. No. 13/960,015. |
Notice of Allowance dated Apr. 13, 2016 in U.S. Appl. No. 13/957,499. |
Advisory Action dated Apr. 18, 2016 in U.S. Appl. No. 13/960,015. |
Amendment filed Jun. 6, 2016 in U.S. Appl. No. 13/960,015. |
Office Action dated Jun. 28, 2016 in U.S. Appl. No. 15/143,742. |
Office Action dated Jul. 21, 2016 in U.S. Appl. No. 13/960,015. |
Office Action dated Jul. 27, 2016 in U.S. Appl. No. 15/163,078. |
Amendment filed Sep. 27, 2016 in U.S. Appl. No. 15/143,742. |
Office Action dated Sep. 5, 2016 in Chinese Patent Application No. 201380072479.3, and English translation thereof. |
Response to Office Action filed Sep. 27, 2016 in European Patent Application No. 13826807.3. |
Notice of Intention to Grant dated Jan. 3, 2017 in European Patent Application No. 13826807.3. |
Notice of Allowance dated Jan. 18, 2017 in U.S. Appl. No. 15/143,742. |
Amendment filed Jan. 19, 2017 in U.S. Appl. No. 13/960,015. |
Response to Office Action filed Jan. 19, 2017 in Chinese Patent Application No. 201380072479.3, and English translation thereof. |
Notice of Allowance dated Feb. 22, 2017 in U.S. Appl. No. 13/960,015. |
Notice of Allowance dated Mar. 15, 2017 in U.S. Appl. No. 15/163,078. |
Office Action dated Mar. 24, 2017 in U.S. Appl. No. 15/372,603. |
Decision to Grant dated May 26, 2017 in European Patent Application No. 13826807.3. |
Office Action dated Jun. 16, 2017 in U.S. Appl. No. 14/652,856. |
Amendment filed Jun. 26, 2017 in U.S. Appl. No. 15/372,603. |
Partial European Search Report dated Jul. 25, 2017 in European Patent Application No. 17169068.8. |
Extended European Search Report dated Jul. 25, 2017 in European Patent Application No. 14871226.8. |
PCT Invitation to Pay Additional Fees dated Aug. 3, 2017 in International Application No. PCT/US2017/028715. |
Office Action dated Aug. 11, 2017 in European Patent Application No. 14871226.8. |
Notice of Allowance dated Sep. 11, 2017 in U.S. Appl. No. 15/372,603. |
Amendment Filed Sep. 18, 2017 in U.S. Appl. No. 14/652,856. |
Office Action dated Sep. 21, 2017 in U.S. Appl. No. 15/628,870. |
Office Action dated Sep. 27, 2017 in U.S. Appl. No. 15/589,134. |
International Search Report and Written Opinion dated Oct. 3, 2017 in International Application No. PCT/US2017/028715. |
Chaliki, HP et al.; “Pulmonary Venous Pressure: Relationship to Pulmonary Artery, Pulmonary Wedge, and Left Atrial Pressure in Normal, Lightly Sedated Dogs”; Catheterization and Cardiovascular Interventions; vol. 56, Issue 3; Jun. 17, 2002; p. 432, Abstract. |
Office Action dated Oct. 19, 2017 in Japanese Patent Application No. 2015-549718, and English translation thereof. |
Restriction and Election of Species Requirement dated Oct. 20, 2017 in U.S. Appl. No. 15/092,737. |
Office Action dated Nov. 6, 2017 in Australian Patent Application No. 2013361318. |
Notice of Allowance dated Nov. 25, 2020 in Korean Patent Application No. 10-2015-7019640, and English translation thereof. |
Response to Office Action dated Dec. 10, 2020 in European Patent Application No. 16845150.8. |
Final Office Action dated Dec. 14, 2020 in U.S. Appl. No. 16/359,218. |
Response to Office Action dated Dec. 22, 2020 in Korean Patent Application No. 10-2016-7019183, and machine English translation thereof. |
Examination Report dated Dec. 31, 2020 in Indian Patent Application No. 4286/CHENP/2015. |
Intention to Grant dated Jan. 12, 2021 in European Patent Application No. 19 196 148.1. |
Decision to Grant a Patent dated Jan. 14, 2021 in Japanese Patent No. 2018-238255, and English translation thereof. |
Response Second Office Action dated Jan. 25, 2021 in Canadian Patent Application No. 2893222. |
Response to Second Office Action dated Jan. 27, 2021 in Chinese Patent Application No. 2017109301826, and English translation thereof. |
Response to Office Action filed Feb. 11, 2021 in U.S. Appl. No. 16/840,673. |
Klabunde, Richard E., “Determinants of Myocardial Oxygen Consumption,” Cardiovascular Physiology Concepts, Apr. 3, 2007, retrieved Oct. 7, 2016 from: <URL: https://web.archive.org/web/20070403052549/http://www.cvphysiology.com/CAD/CAD004.htm>, 2 pages. |
Office Action dated Sep. 22, 2015 in U.S. Appl. No. 13/884,144. |
Amendment filed Dec. 4, 2015 in U.S. Appl. No. 13/884,144. |
Final Office Action dated Jan. 21, 2016 in U.S. Appl. No. 13/884,144. |
Amendment filed Apr. 14, 2016 in U.S. Appl. No. 13/884,144. |
Office Action dated Jun. 10, 2016 in U.S. Appl. No. 13/884,144. |
Interview Summary dated Jul. 14, 2016 in U.S. Appl. No. 13/884,144. |
Amendment filed Aug. 15, 2016 in U.S. Appl. No. 13/884,144. |
Notice of Allowance dated Sep. 1, 2016 in U.S. Appl. No. 13/884,144. |
Amendment filed Oct. 26, 2016 in U.S. Appl. No. 15/163,078. |
PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority; International Search Report; and Written Opinion, dated Nov. 28, 2016 in International Application No. PCT/US2016/051023. |
Arbel E.R., et al., “Successful Treatment of Drug-Resistant Atrial Tachycardia and Intractable Congestive Heart Failure with Permanent Coupled Atrial Pacing,” The American Journal of Cardiology, 1978, vol. 41 (2), pp. 336-340. |
Auricchio A., et al., “Cardiac Resyncbronization Therapy Restores Optimal Atrioventricular Mechanical Timing in Heart Failure Patients With Ventricular Conduction Delay,” Journal of the American College of Cardiology, 2002, vol. 39 (7), pp. 1163-1169. |
Auricchio A., et al., “Effect of Pacing Chamber and Atrioventricular Delay on Acute Systolic Function of Paced Patients With Congestive Heart Failure,” Circulation—Journal of the American Heart Association, 1999, vol. 99 (23), pp. 2993-3001. |
Braunwald E., et al., “Editorial: Paired Electrical Stimulation of the Heart: A Physiologic Riddle and a Clinical Challenge,” Circulation, 1965, vol. 32 (5), pp. 677-681. |
Calderone A., et al., “The Therapeutic Effect of Natriuretic Peptides in Heart Failure; Differential Regulation of Endothelial and Inducible Nitric Oxide Synthases,” Heart Failure Reviews, 2003, vol. 8 (1), pp. 55-70. |
Han B., et al., “Cardiovascular Effects of Natriuretic Peptides and Their Interrelation with Endothelin-1,” Cardiovascular Drugs and Therapy, 2003, vol. 17 (1), pp. 41-52. |
Information Manual, Model 5837 R-Wave Coupled Pulse Generator, Prelim. Ed. III , Medtronic, 1965, 20 pages. |
PCT Notification Concerning Transmittal of International Preliminary Report on Patentability (IPER), International Application No. PCT/US2005/028415, from the International Bureau dated Feb. 21, 2008. |
International Search Report and Written Opinion for Application No. PCT/US2005/28415, dated Jan. 19, 2006. |
International Search Report and Written Opinion for Application No. PCT/US2014/042777, dated Jan. 2, 2015. |
Invitation to Pay Additional Fees dated Oct. 17, 2014 in International Application No. PCT/US2014/042777. |
Kerwin W.F., et al., “Ventricular Contraction Abnormalities in Dilated Cardiomyopathy: Effect of Biventricular Pacing to Correct Interventricular Dyssynchrony,” Journal of the American College of Cardiology, 2000, vol. 35 (5), pp. 1221-1227. |
Lister J.W., et al.,“The Hemodynamic Effect of Slowing the Heart Rate by Paired or Coupled Stimulation of the Atria,” American Heart Journal, 1967, vol. 73 (3), pp. 362-368. |
Liu L., et al., “Left Ventricular Resynchronization Therapy in a Canine Model of Left Bundle Branch Block,” American Journal of Physiology—Heart and Circulatory Physiology, 2002, vol. 282 (6), pp. H2238-H2244. |
Lopez J.F., et al., “Reducing Heart Rate of the Dog by Electrical Stimulation,” Circulation Research, 1964, vol. 15, pp. 414-429. |
Nishimura K., et al., “Atrial Pacing Stimulates Secretion of Atrial Natriuretic Polypeptide without Elevation of Atrial Pressure in Awake Dogs with Experimental Complete Atrioventricular Block,” Circulation Research, 1990, vol. 66 (1), pp. 115-122. |
Notice of Allowance dated Dec. 16, 2014 in U.S. Appl. No. 13/826,215. |
O'Cochlain B., et al., “The Effect of Variation in the Interval Between Right and Left Ventricular Activation on Paced QRS Duration,” Journal of Pacing and Clinical Electrophysiology, 2001, vol. 24 (12), pp. 1780-1782. |
Pappone C., et al., “Cardiac Pacing in Heart Failure Patients with Left Bundle Branch Block: Impact of Pacing Site for Optimizing Left Ventricular Resynchronization,” Italian Heart Journal, 2000, vol. 1 (7), pp. 464-469. |
PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority; Declaration of Non-Establishment of International Search Report; and PCT Written Opinion of International Searching Authority, dated Apr. 24, 2014 in International Application No. PCT/US2013/076600. |
Perego G.B., et al., “Simultaneous Vs. Sequential Biventricular Pacing in Dilated Cardiomyopathy: An Acute Hemodynamic Study,” The European Journal of Heart Failure, 2003, vol. 5 (3), pp. 305-313. |
Schoonderwoerd B.A., et al., “Atrial Natriuretic Peptides During Experimental Atrial Tachycardia: Role of Developing Tachycardiomyopathy,” Journal of Cardiovascular Electrophysiology, 2004, vol. 15 (8), pp. 927-932. |
Siddons et al., Cardiac Pacemakers, Pub. No. 680 of American Lecture Series, 1968, Thomas C. Publisher, pp. 200-217. |
Verbeek X.A., et al., “Intra-Ventricular Resynchronization for Optimal Left Ventricular Function During Pacing in Experimental Left Bundle Branch Block,” Journal of American College of Cardiology, 2003, vol. 42 (3), pp. 558-567. |
Verbeek X.A., et al., “Quantification of Interventricular Asynchrony during LBBB and Ventricular Pacing,” American Journal of Physiology—Heart and Circulatory Physiology, 2002, vol. 283 (4), pp. H1370-H1378. |
Whinnett Z.I., et al., “Haemodynannic Effects of Changes in Atrioventricular and Interventricular Delay in Cardiac Resynchronization Therapy Show a Consistent Pattern: Analysis of Shape, Magnitude and Relative Importance of Atrioventricular and Interventricular Delay,” Heart, 2006, vol. 92 (11), pp. 1628-1634. |
Willems R., et al., “Different Patterns of Angiotensin II and Atrial Natriuretic Peptide Secretion in a Sheep Model of Atrial Fibrillation,” Journal of the Cardiovascular Electrophysiology, 2001, vol. 12 (12), pp. 1387-1392. |
Zupan I., et al., “Effects of Systolic Atrial Function on Plasma Renin Activity and Natriuretic Peptide Secretion after High Rate Atrial and Ventricular Pacing in Dogs,” Pacing and Clinical Electrophysiology, 2005, vol. 28 (Supp 1), pp. S270-S274. |
Office Action dated Jan. 29, 2015 in U.S. Appl. No. 13/688,978. |
Office Action dated May 4, 2015 in U.S. Appl. No. 13/854,283. |
Office Action dated Jun. 4, 2015 in U.S. Appl. No. 13/957,499. |
Office Action dated Jun. 10, 2015 in U.S. Appl. No. 13/960,015. |
Office Action dated Jul. 13, 2015 in U.S. Appl. No. 14/642,952. |
Office Action dated Aug. 14, 2015 in U.S. Appl. No. 13/688,978. |
Amendment filed Oct. 9, 2015 in U.S. Appl. No. 14/642,952. |
Amendment filed Oct. 16, 2015 in U.S. Appl. No. 14/854,283. |
Amendment filed Nov. 5, 2015 in U.S. Appl. No. 13/688,978. |
Office Action dated Nov. 4, 2015 in U.S. Appl. No. 14/427,478. |
Amendment filed Nov. 30, 2015 in U.S. Appl. No. 13/957,499. |
Office Action dated Feb. 4, 2020 in Canada Patent Application No. 2893222. |
Extended European Search Report dated Mar. 25, 2020 in European Patent Application No. 19196148.1. |
Notice of Intention to Grant dated Mar. 26, 2020 in European Patent Application No. 18205392.6. |
Office Action dated Apr. 28, 2020 in European Patent Application No. 19196148.1. |
Response to Office Action filed May 5, 2020 in Canada Patent Application No. 2893222. |
Office Action dated May 7, 2020 in Japanese Patent No. 2019-072248, and English translation thereof. |
Response to Office Action filed May 12, 2020 in Japanese Patent Application No. 2018-238255, and English translation thereof. |
Office Action dated May 15, 2020 in Korean Patent No. 10-2015-7019640, and English translation thereof. |
Office Action dated May 19, 2020 in Australian Patent No. 2016319787. |
Response to Office Action filed Jun. 3, 2020 in European Patent Application No. 17786669.6. |
Office Action dated Jun. 4, 2020 in European Patent Application No. 16845150.8. |
Office Action dated Jun. 8, 2020 in U.S. Appl. No. 16/359,218. |
Response to Office Action filed Jun. 19, 2020 Japanese Patent No. 2019-072248, and English translation thereof. |
Office Action dated May 12, 2021 in Korean Patent Application No. 10-2021-7005394, and English translation thereof. |
Notice of Acceptance dated May 18, 2021 in Australian Patent Application No. 2016319787. |
First Examination Report dated May 20, 2021 in Indian Patent Application No. 201847042937. |
Notice of Intention to Grant dated May 21, 2021 in European Patent Application No. 16 845 150.8. |
Notice of Intention to Grant dated Jun. 2, 2021 in European Patent Application No. 17 786 669.6. |
Notice of Acceptance dated Jun. 15, 2021 in Australian Patent Application No. 2019204758. |
Response to Office Action filed Jun. 17, 2021 in Canadian Patent Application No. 2,893,222. |
First Examination Report dated Jun. 18, 2021 in Australian Patent Application No. 2017252310. |
Response to Office Action filed Jul. 8, 2021 in Korean Patent Application No. 10-2021-7005394, and machine English translation thereof. |
Request for Trial and Amendment filed Aug. 2, 2021 in Japanese Patent Application No. 2018-512118, and machine English translation thereof. |
Notice of Allowance dated Jul. 21, 2021 in Korean Patent Application No. 10-2016-7019183, and English translation thereof. |
Response to First Examination Report dated Sep. 3, 2020 in Australian Patent Application No. 2019204758. |
Response to First Examination Report dated Oct. 2, 2020 in Australian Patent Application No. 2016319787. |
Response to Office Action dated Oct. 5, 2020 in Japanese Patent Application No. 2018-512118, and English translation thereof. |
Amendment filed Oct. 8, 2020 in U.S. Appl. No. 16/359,218. |
Response to Office Action dated Oct. 20, 2020 in European Patent Application No. 19 196 148.1. |
Response to Office Action dated Oct. 26, 2020 in Chinese Patent Application No. 2017109301826, and English translation thereof. |
Office Action dated Nov. 12, 2020 in U.S. Appl. No. 16/840,673. |
Response to Office Action dated Nov. 13, 2020 in Japanese Patent Application No. 2018-238255, and English translation thereof. |
Certificate of Grant dated Oct. 1, 2020 in Australian Patent Application No. 2018217270. |
Second Examination Report dated Oct. 1, 2020 in Australian Patent Application No. 2019204758. |
Second Office Action dated Oct. 5, 2020 in Canadian Patent Application No. 2893222. |
Office Action dated Oct. 23, 2020 in Korean Patent Application No. 10-2016-7019183, and English translation thereof. |
Second Examination Report dated Oct. 26, 2020 in Australian Patent Application No. 2016319787. |
Office Action dated Nov. 5, 2020 in European Patent Application No. 17786669.6. |
Office Action dated Nov. 9, 2020 in Canadian Patent Application No. 2933278. |
Office Action dated Nov. 13, 2020 in Chinese Patent Application No. 2017109301826, and English translation thereof. |
Decision to Grant a Patent dated Nov. 26, 2020 in Japanese Patent No. 2019-072248, and English translation thereof. |
Notice of Allowance dated Nov. 19, 2020 in U.S. Appl. No. 16/276,958. |
Amendment filed Sep. 22, 2020 in U.S. Appl. No. 16/276,958. |
Response to Restriction and Election of Species Requirement filed Dec. 8, 2017 in U.S. Appl. No. 15/092,737. |
Office Action dated Dec. 27, 2017 in U.S. Appl. No. 15/092,737. |
Amendment and Declaration Under 37 CFR 1.132 filed Jan. 22, 2018 in U.S. Appl. No. 15/628,870. |
Amendment filed Jan. 26, 2018 in U.S. Appl. No. 15/589,134. |
Notice of Allowance dated Dec. 6, 2017 in U.S. Appl. No. 14/652,856. |
Supplemental Notice of Allowance dated Jan. 29, 2018 in U.S. Appl. No. 14/652,856. |
Extended European Search Report dated Nov. 3, 2017 in European Patent Application No. 17169068.8. |
Response to Office Action filed Feb. 7, 2018 in European Patent Application No. 14871226.8. |
Response to Office Action filed Mar. 28, 2018 in Japanese Patent Application No. 2015-549718, with machine English translation of Remarks and English translation of Amended Claims. |
Interview Summary dated Apr. 3, 2018 in U.S. Appl. No. 15/092,737. |
Office Action dated Feb. 24, 2018 in Chinese Patent Application No. 201480075987.1, and English translation thereof. |
Notification Concerning Transmittal of International Preliminary Report on Patentability (IPRP) dated Mar. 22, 2018 in International Application No. PCT/2016/051023. |
Response to Examination Report filed Apr. 23, 2018 in Australian Patent Application No. 2013361318. |
Amendment filed Apr. 24, 2018 in U.S. Appl. No. 15/092,737. |
Notice of Allowance dated May 2, 2018 in U.S. Appl. No. 15/589,134. |
Office Action dated May 16, 2018 in U.S. Appl. No. 15/628,870. |
Office Action dated May 16, 2018 in U.S. Appl. No. 15/851,787. |
Response to Extended European Search Report filed May 25, 2018 in European Patent Application No. 17 169 068.8. |
Response to Office Action filed Jul. 11, 2018 in Chinese Patent Application No. 201480075987.1, and English machine translation thereof. |
Notice of Acceptance dated May 7, 2018 in Australian Patent Application No. 2013361318. |
Notice of Intention to Grant dated May 7, 2018 in European Patent Application No. 14871226.8. |
Office Action dated May 10, 2018 in Japanese Patent Application No. 2016-539929, and English translation thereof. |
Office Action dated Aug. 9, 2018 in U.S. Appl. No. 15/911,249. |
Response to Office Action filed Aug. 13, 2018 in U.S. Appl. No. 15/628,870. |
Amendment filed Aug. 13, 2018 in U.S. Appl. No. 15/851,787. |
Restriction Requirement dated Sep. 24, 2018 in U.S. Appl. No. 15/226,056. |
Response to Final Office Action filed Oct. 24, 2018 in Japanese Patent Application No. 2015-549718, with English Translation of Amended Claims and English Machine Translation of Remarks. |
Notice of Allowance dated Oct. 29, 2018 in U.S. Appl. No. 15/092,737. |
Response to Office Action filed Oct. 29, 2018 in Japanese Patent Application No. 2016-539929, with English Translation of Amended Claims and English Machine Translation of Remarks. |
Notice of Allowance dated Oct. 31, 2018 in U.S. Appl. No. 15/851,787. |
Restriction Requirement dated Nov. 1, 2018 in U.S. Appl. No. 15/492,802. |
Notice of Allowance dated Nov. 26, 2018 in U.S. Appl. No. 15/628,870. |
Amendment and Response to Restriction Requirement filed Nov. 26, 2018 in U.S. Appl. No. 15/226,056. |
Interview Summary dated Dec. 12, 2018 in U.S. Appl. No. 15/911,249. |
Response to Restriction Requirement filed Dec. 19, 2018 in U.S. Appl. No. 15/492,802. |
Office Action dated Dec. 27, 2018 in U.S. Appl. No. 16/124,283. |
Amendment filed Jan. 9, 2019 in U.S. Appl. No. 15/911,249. |
Office Action dated Jan. 11, 2019 in U.S. Appl. No. 15/226,056. |
Decision to Grant a Patent dated Dec. 6, 2018 in Japanese Patent Application No. 2016-539929, with English translation thereof. |
First Examination Report dated Dec. 12, 2018 in Australian Patent Application No. 2014367229. |
Final Office Action dated Aug. 28, 2018 in Japanese Patent No. 2015-549718, and English translation thereof. |
Notification Concerning Transmittal of International Preliminary Report On Patentability (IPRP) dated Nov. 1, 2018 in International Application No. PCT/2017/028715. |
Response to Examination Report filed Feb. 22, 2019 in Australian Patent Application No. 2014367229. |
Office Action dated Mar. 18, 2019 in U.S. Appl. No. 15/492,802. |
Notice of Allowance dated Mar. 19, 2019 in U.S. Appl. No. 15/613,344. |
Response to Office Action filed Mar. 27, 2019 in U.S. Appl. No. 16/124,283. |
Office Action dated Apr. 8, 2019 in U.S. Appl. No. 15/911,249. |
Amendment filed Apr. 10, 2019 in U.S. Appl. No. 15/226,056. |
Notice of Allowance dated Mar. 3, 2021 in Chinese Patent Application No. 2017109301826, with machine English translation thereof. |
Office Action dated Mar. 29, 2021 in Chinese Patent Application No. 2016800526048, with machine English translation thereof. |
Office Action dated Apr. 1, 2021 in Japanese Patent Application No. 2018-554557, with English translation thereof. |
Decision of Refusal dated Apr. 8, 2021 in Japanese Patent Application No. 2018-512118, with English translation thereof. |
Decision to Grant dated Apr. 15, 2021 in European Patent Application No. 19196148.1. |
Response After Final Rejection filed Feb. 24, 2021 in U.S. Appl. No. 16/359,218. |
Response to Office Action dated Mar. 5, 2021 in Canadian Patent Application No. 2933278. |
Response to Second Office Action dated Mar. 11, 2021 in European Patent Application No. 17 786 669.6. |
Notice of Allowance dated Mar. 29, 2021 in U.S. Appl. No. 16/359,218. |
Notice of Allowance dated Apr. 21, 2021 in U.S. Appl. No. 16/840,673. |
Response to Examiner's report filed May 7, 2021 in Australian Patent Application No. 2016319787. |
Notice of Acceptance dated Jun. 5, 2020 in Australian Patent Application No. 2018217270. |
Office Action dated Jun. 9, 2020 in Chinese Patent Application No. 2017109301826, and English machine translation thereof. |
First Examination Report dated Jun. 22, 2020 in Australian Patent Application No. 2019204758. |
Office Action dated Jun. 23, 2020 in U.S. Appl. No. 16/276,958. |
Response to Office Action filed Jul. 10, 2020 in Korean Patent Application No. 10-2015-7019640, and English machine translation thereof. |
Office Action dated Jul. 30, 2020 in Japanese Patent No. 2018-238255, and English translation thereof. |
Office Action dated Jul. 30, 2020 in Japanese Patent No. 2018-512118, and English translation thereof. |
Decision to Grant a Patent dated Mar. 7, 2019 in Japanese Patent Application No. 2015-549718, and English translation thereof. |
Notice of Acceptance dated Mar. 22, 2019 in Australian Patent Application No. 2014367229. |
Extended European Search Report dated Mar. 27, 2019 in European Patent Application No. 16845150.8. |
Notice of Intention to Grant dated May 10, 2019 in European Patent Application No. 17169068.8. |
Notice of Allowance dated Jun. 5, 2019 in U.S. Appl. No. 16/124,283. |
Amendment filed Jun. 14, 2019 in U.S. Appl. No. 15/492,802. |
Notice of Allowance dated Jul. 2, 2019 in U.S. Appl. No. 15/492,802. |
Amendment filed Jul. 8, 2019 in U.S. Appl. No. 15/911,249. |
Extended European Search Report dated Jan. 21, 2019 in European Patent Application No. 18205392.6. |
First Examination Report dated Jun. 25, 2019 in Australian Patent Application No. 2018217270. |
Final Office Action dated Jul. 29, 2019 in U.S. Appl. No. 15/226,056. |
Final Office Action dated Aug. 30, 2019 in U.S. Appl. No. 15/911,249. |
Response to Office Action filed Sep. 9, 2019 and Sep. 18, 2019 in European Patent Application No. 18205392.6. |
Response to Office Action filed Aug. 12, 2021 in Chinese Patent Application No. 2016800526048, and English translation thereof. |
Restriction Requirement dated Aug. 17, 2021 in U.S. Appl. No. 16/281,218. |
Response to First Examination Report filed Aug. 19, 2021 in Indian Patent Application No. 4286/CHENP/2015. |
Office Action dated Sep. 15, 2021 in U.S. Appl. No. 16/583,371. |
Response to Office Action filed Sep. 28, 2021 in Japanese Patent Application No. 2018-554557, and machine English translation thereof. |
Office Action dated Oct. 29, 2021 in U.S. Appl. No. 16/281,218. |
Response to Second Office Action filed Nov. 4, 2021 in Chinese Patent Application No. 2016800526048, and English translation thereof. |
Response to Office Action filed Dec. 9, 2021 in U.S. Appl. No. 16/583,371. |
Office Action dated Dec. 21, 2021 in U.S. Appl. No. 16/663,573. |
Response to Office Action filed Dec. 22, 2021 in Japanese Patent Application No. 2020-189356, with machine English translation thereof. |
Response to Second Office Action filed Jan. 5, 2022 in Canadian Patent Application No. 2933278. |
Response to First Examination Report filed Jan. 20, 2022 in Australian Patent Application No. 2017252310. |
Amendment filed Jan. 26, 2022 in U.S. Appl. No. 16/281,218. |
Interview Summary dated Jan. 26, 2022 in U.S. Appl. No. 16/281,218. |
Notice of Allowance dated Jan. 26, 2022 in U.S. Appl. No. 16/583,371. |
Response to the First Examination Report filed Feb. 8, 2022 in Indian Patent Application No. 201847042937. |
Second Examination Report dated Feb. 8, 2022 in Australian Patent Application No. 2017252310. |
First Office Action dated Feb. 10, 2022 in Korean Patent Application No. 10-2021-7035610, and machine English translation thereof. |
Response to First Office Action filed Feb. 18, 2022 in Japanese Patent Application No. JP2021-002191, with machine English translation thereof and English translation of claims. |
Notice of Allowance dated Nov. 26, 2021 in Korean Patent Application No. 10-2021-7005394, with machine English translation thereof. |
Office Action dated Dec. 9, 2021 in Japanese Patent Application No. 2021-002191, and English translation thereof. |
Office Action dated Dec. 13, 2021 in Chinese Patent Application No. 2018113777986, and machine English translation thereof. |
Partial European Search Report and Provisional Opinion dated Jan. 5, 2022 in European Patent Application No. 21 201 099.5. |
Notice of Allowance dated Jan. 6, 2022 in Chinese Patent Application No. 2016800526048, and machine English translation thereof. |
Zhigao, Hao, “Dual-channel disease in the atrioventricular node,” International Journal of Cardiovascular Diseases, 1989, p. 248, Vol No. 1990083, and machine English translation thereof. |
Iliescu, Radu, et al. “Mechanisms of Blood Pressure Reduction by Prolonged Activation of the Baroreflex,” 31st Annual International Conference of the IEEE EMBS, Minneapolis, Minnesota, USA, Sep. 2-6, 2009, p. 2040-2042. |
Second Office Action dated Aug. 26, 2021 in Chinese Patent Application No. 2016800526048, and machine English translation thereof. |
Second Office Action dated Sep. 9, 2021 in Canadian Patent Application No. 2,933,278. |
Notice of Allowance dated Sep. 24, 2021 in Canadian Patent Application No. 2,893,222. |
Office Action dated Sep. 30, 2021 in Japanese Patent Application No. 2020-189356, and English translation thereof. |
Decision to Grant dated Oct. 7, 2021 in European Patent Application No. 16 845 150.8. |
First Examination Report dated Oct. 8, 2021 in Indian Patent Application No. 201847012769. |
Decision to Grant dated Oct. 21, 2021 in European Patent Application No. 17 786 669.6. |
Office Action dated Mar. 3, 2022 in U.S. Appl. No. 16/794,478. |
Amendment filed Mar. 16, 2022 in U.S. Appl. No. 16/663,573. |
Notice of Allowance dated Mar. 30, 2022 in U.S. Appl. No. 16/281,218. |
Response to First Examination Report filed Apr. 6, 2022 in Indian Application No. 201847012769. |
Response to Office Action filed Apr. 11, 2022 in Korean Patent Application No. 10-2021-7035610, and machine English translation thereof. |
Response to Office Action filed Apr. 25, 2022 in Chinese Patent Application No. 2018113777986 and English translation thereof. |
Notice of Allowance dated Apr. 29, 2022 in U.S. Appl. No. 16/663,573. |
Response to Second Examination Report filed May 4, 2022 in Australian Application No. 2017252310. |
Notice of Allowance dated May 6, 2022 in U.S. Appl. No. 16/583,371. |
Decision to Grant dated Mar. 3, 2022 in Japanese Patent Application No. JP2018-554557, and English translation thereof. |
First Examination Report dated Mar. 17, 2022 in Indian Patent Application No. 202148037573. |
Extended European Search Report dated Apr. 7, 2022 in European Patent Application No. 21201099.5. |
Hearing Notice dated Apr. 26, 2022 in Indian Patent Application No. 4286/CHENP/2015. |
Number | Date | Country | |
---|---|---|---|
20190351237 A1 | Nov 2019 | US |
Number | Date | Country | |
---|---|---|---|
62217299 | Sep 2015 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15259282 | Sep 2016 | US |
Child | 16431776 | US |